Skip to main content

Rare Diseases NHS Update

06 Oct 2022 13:00 - 14:00

Rare Diseases NHS Update
Click to enlarge

I am the founder of Oxygen - a strategic healthcare public affairs company based in the new diplomatic precinct of Nine Elms in London.

more about Henry

Shailen has had a leading involvement in well over 300 partnership working projects over his career - initially working in the NHS and latterly under the banner of Soar Beyond Ltd

more about Shailen

A pharmaceutical market access specialist with more than 20 years’ experience of tracking access environments around the world. 

more about Neil

Treatment and funding decisions for rare diseases have in the main shifted from NHS England to integrated care systems (ICSs). Much more than a simple change in policy, the intention is to create an integrated and cooperative system of care that operated at pan-ICS and individual levels.

How should companies who provide pharmaceuticals and technologies for this specialised area of medicine respond to this paradigm-shift in policy?

In October's FREE 60-minute LIVE Think Tank , our experts will explain how the new system operates, what will change and how you can become a part of the rare diseases new world, working with your customers to maximise opportunities and outcomes.



  • How rare diseases will be managed in the ICS-era
  • How to engage with the new system
  • The key players and decision makers
  • Where resources will be allocated



Sign up using the form below: